Form 4: ADMA Biologics COO Exercises Stock Options, Reduces Holdings After Tax Withholding

ADMA Biologics' COO, Kaitlin M. Kestenberg-Messina, exercised stock options resulting in a net decrease in her directly held shares after accounting for tax obligations.

Summary

• Kaitlin M. Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, exercised 5,000 stock options at a price of $10.80 per share on January 30, 2025.
• The exercise of these options resulted in the acquisition of 5,000 shares of common stock.
• To cover tax obligations and the option exercise price, 3,355 shares were withheld by the issuer at a price of $16.10 per share.
• Following these transactions, Ms. Kestenberg-Messina's direct holdings decreased to 446,232 shares of common stock.
• This total includes 192,320 unvested RSUs granted on April 1, 2024, 22,500 unvested RSUs granted on July 24, 2023, 71,250 unvested RSUs granted on March 6, 2023, 20,000 unvested RSUs granted on March 7, 2022, 5,000 unvested RSUs granted on February 25, 2021, and 135,162 shares of common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to executive compensation. It is neither particularly positive nor negative, but rather a standard disclosure.

Negatives

• The COO's direct shareholdings decreased due to the tax withholding associated with the option exercise.

Risks

• Changes in executive holdings can sometimes be perceived negatively by the market, although this transaction appears to be a routine exercise of vested options.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives exercise stock options or have changes in their beneficial ownership. It is a routine part of executive compensation and transparency.

Comparison to Industry Standards

• The exercise of stock options and subsequent tax withholding is a common practice among publicly traded companies, particularly in the biotech sector.
• Many companies use a combination of stock options and restricted stock units (RSUs) as part of their executive compensation packages, similar to ADMA Biologics.
• Companies like Grifols, CSL Behring, and Takeda also use similar compensation structures for their executives.
• The vesting schedules for RSUs, typically over four years with quarterly installments, are also standard practice in the industry.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects a change in executive ownership, but it is not a significant event.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

ADMA Biologics, stock options, insider trading, Form 4, Kaitlin M. Kestenberg-Messina, executive compensation, share ownership, RSUs